Lots of interesting abstracts and cases were submitted for TCTAP 2023. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP C-006
Case Report: Very Early Vascular Heeling of BioFreedom Ultra in ACS Lesion ~OCT Study~
By Tsuda Takuma
Presenter
Tsuda Takuma
Authors
Tsuda Takuma1
Affiliation
Nagoya Ekisaikai Hospital, Japan1,
View Study Report
TCTAP C-006
CORONARY - Acute Coronary Syndromes (STEMI, NSTE-ACS)
Case Report: Very Early Vascular Heeling of BioFreedom Ultra in ACS Lesion ~OCT Study~
Tsuda Takuma1
Nagoya Ekisaikai Hospital, Japan1,
Clinical Information
Patient initials or Identifier Number
S.S
Relevant Clinical History and Physical Exam
Case1: 82 years old female with ACS. Mid-LCx was culprit.Case2: 83 years old female with ACS. LAD prox and mid were culprit.Case3: 81 years old male with ACS. LAD ostial and mid were culprit with severe calcification.
Relevant Test Results Prior to Catheterization
Relevant Catheterization Findings
Case1: CAG showed #13 90%.Case2: CAG showed #6-7 99%.Case3: CAG showed #6os 90%, #7 90%.
Interventional Management
Procedural Step
Case1: Mid-LCx was culprit and well treated by BioFreedom ULTRA2.5/14. OCT assessed this stent after 11 days and showed that percentage of uncovered stentstrut and malapposed stent strut was 20.6% and 1.6%, respectively.
Case2: LAD prox and mid were culprit. Proximal lesion and mid lesion was fixed by BioFreedom ULTRA3.5/26 and 2.5/22 respectively. OCT assessed this stent after 14 days and showed that percentage of covered stent strut and malapposed stent strut was lower in BioFreedom ULTRA (29.5% vs 41.7% and 2.4% vs 8.9%, respectively).
Case3: LAD ostial and mid were culprit with severe calcification and treated by Rotablator. Proximal lesion and mid lesion was fixed by Combo plus3.5/18 and BioFreedom ULTRA3.0/14, respectively. OCT assessed this stent after 10 days and showed that percentage of covered stent strut and malapposed stent strut was lower in BioFreedom ULTRA (33.9% vs 3.0% and 1.7% vs 12.6%, respectively).
Case2: LAD prox and mid were culprit. Proximal lesion and mid lesion was fixed by BioFreedom ULTRA3.5/26 and 2.5/22 respectively. OCT assessed this stent after 14 days and showed that percentage of covered stent strut and malapposed stent strut was lower in BioFreedom ULTRA (29.5% vs 41.7% and 2.4% vs 8.9%, respectively).
Case3: LAD ostial and mid were culprit with severe calcification and treated by Rotablator. Proximal lesion and mid lesion was fixed by Combo plus3.5/18 and BioFreedom ULTRA3.0/14, respectively. OCT assessed this stent after 10 days and showed that percentage of covered stent strut and malapposed stent strut was lower in BioFreedom ULTRA (33.9% vs 3.0% and 1.7% vs 12.6%, respectively).
Case Summary
New drug coating stent, BioFreedom ULTRA, could have potential of earlier vascular heeling response due to thinner stent and polymer-free drug delivery system, which could also contribute to ACS with HBR patient.